"10.1371_journal.pone.0123904","plos one","2015-04-13T00:00:00Z","Laura Ciarloni; Sahar Hosseinian; Sylvain Monnier-Benoit; Natsuko Imaizumi; Gian Dorta; Curzio Ruegg; On behalf of the DGNP-COL-0310 Study Group","Diagnoplex SA, Epalinges, Switzerland; Novigenix SA, Epalinges, Switzerland; National Center for Competence in Research (NCCR), Molecular Oncology, Swiss Institute for Experimental Cancer Research (ISREC)-Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland; Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland; Department of Medicine, Faculty of Science, University of Fribourg, Fribourg, Switzerland","Conceived and designed the experiments: LC SH SMB NI GD CR. Performed the experiments: LC SMB SH. Analyzed the data: LC SMB SH. Contributed reagents/materials/analysis tools: SH GD. Wrote the paper: LC SH SMB CR. Writing clinical protocol: NI GD.","LC SH SMB NI were employees of Diagnoplex SA at the time of the study. Also, they own stock options in Diagnoplex SA. CR is a co-founder, advisory board member and owns stocks and shares of Diagnoplex SA. GD has served as speaker, consultant and advisory board member for Diagnoplex SA, and has received research funding from Diagnoplex SA. This does not alter our adherence to PLOS ONE policies on sharing data and materials.","2015","04","Laura Ciarloni","LC",7,TRUE,6,3,3,4,TRUE,TRUE,TRUE,1,"7",TRUE
